Increased incidence of and survival from breast cancer have resulted in growth of the number of women who have surviyed this disease and are faced with the subsequent consequences of their diagnosis and treatment: Physical activity is a modifiable health behavior that has the potential to address both the emotional and physical needs of women with early stage breast cancer. However, for physical activity to be seen as a viable treatment option, and for a change in routine care to occur, its effectiveness must be determined. Accordingly, the objectives of this pilot study are to; 1) quantify the effect of a 12-week home-based walking intervention on quality of life, body composition, and estrogen metabolism in survivors of breast cancer, and 2) develop and test the feasibility of physical activity intervention materials for future studies in this population. We hypothesize that women randomized to the walking intervention will report higher levels of quality of life, experiehce less weight gain, and have more favorable estrogen metabolite profiles.
The recruitment of participants into this study has not yet been initiated due to challenges in institutional agreements regarding coverage of potential medical expenses incurred by women as a consequence of their participation in this research. However, this issue has been resolved, and we plan to begin recruitment in late November. 
Introduction
Increased incidence of and survival from breast cancer have resulted in growth of the number of women who have survived this disease and are faced with the subsequent consequences. Diagnosis and treatment of breast cancer are associated with several adverse physical and psychosocial outcomes (e.g., weight gain, reduced physical activity levels, loss of lean body mass, depression, lowered self-esteem). Some of these adverse effects are attenuated after adjuvant treatment ends. However, psychological distress and weight gain may persist, resulting in reduced quality of life and increased risk of recurrence. Physical activity participation may attenuate the adverse effects outlined above and improve hormonal factors that influence breast cancer recurrence (1). Given these benefits, it is remarkable that physical activity programs have not been adapted for breast cancer survivors until very recently. In order for physical activity to be seen as a viable treatment option, and for a change in routine care to occur, its effectiveness must be determined. Accordingly, the objectives of this pilot study are to; 1) quantify the effect of a 12-week home-based walking intervention on quality of life, body composition, and estrogen metabolism in survivors of breast cancer, and 2) develop and test the feasibility of physical activity intervention materials for future studies in this population. We hypothesize that women randomized to the walking intervention will report higher levels of quality of life, experience less weight gain, and have more favorable estrogen metabolite profiles. Body DESIGN. Fifty postmenopausal women recently diagnosed with breast cancer will be recruited from the South Carolina Cancer Center (Columbia, SC). Thirty women will be randomized to a 12-week walking intervention and 20 women to a control group. The control group will be offered a walking program following the randomized experiment to allow them benefit from the intervention and improve compliance during the trial. All women will be screened for contraindications to the moderateintensity walking program (i.e., anemia, immune suppression, extreme fatigue, bone pain, and symptoms of cardiovascular disease and orthopedic problems) and excluded as necessary. The intervention will occur after treatment is completed. Experimental groups will be balanced by stage of breast cancer and treatment type.
INTERVENTION. Participants randomized to the intervention will complete a 12-week home-based walking program using the Stanford model developed and refined by King and colleagues (1). Supervised home-based programs are preferred by most adults (5) and have been shown to be safe even in older ages and the obese. To maximize safety, participants will be instructed to gradually increase their walking duration and intensity. By the eighth week of the intervention, the goal will be to walk for 30-40 minutes, 5 times per week, at a moderate intensity level (i.e., 3-4 mph). Women in the intervention will have an initial in-person counseling session with a health educator that will emphasize physical activity safety (i.e., perceived exertion, warm-up, and cool-down). They also will receive 5 brief telephone calls by a health educator to monitor participant safety and enhance adherence during the 12-week intervention. Adherence will be monitored with self-report logs and pedometers. Dr. Sara Wilcox, a psychologist and Associate Professor in Exercise Science at USC, will oversee the intervention.
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OUTCOMES. Quality of life will be measured with the Medical Outcomes Study SF-36 that evaluates eight domains of life quality (e.g., physical, social, bodily pain, mental health). Changes in body mass and composition will be quantified with anthropometric measures and bioelectrical impedance. Estrogen metabolite levels will be measured among half of the overall sample (n=25) from spot urine samples in triplicate using the Estramet 2/16 kit (Immuna Care Corp, Bethlehem, PA). Women in the estrogen sub-study will only be included if they are overweight (i.e., body mass index > 25 kg/M 2 ). The assay is a direct measure of 2-hydroxyestrone and 16alpha-hydroxyestrone. CYP1A2 activity, an enzyme regulating 2-hydroxyestrone formation, will be measured in urine. These markers of estrogen metabolism have been associated with breast cancer risk and physical activity levels. Changes in physical activity will be assessed by questionnaire and an accelerometer (2, 4). Outcomes will be measured at baseline, 6-, and 12-weeks. Availability of these data allow for examination of the effect of the intervention in returning women toward pre-diagnosis levels of physical and psychosocial health.
SUMMARY. This pilot study evaluates the effectiveness of a generalizable physical activity intervention for improving quality of life and two biologic factors associated with prognosis in postmenopausal breast cancer survivors. These data will provide the necessary quantitative estimates of outcome effect sizes that will be used for submission of a larger-scale proposal to rigorously test the hypotheses outlined above. This work has the potential to add an important new treatment option for the growing population of breast cancer survivors.
